REOLYSIN

Phase 2Biologic

OOncolytics Biotech

REOLYSIN is one of 349 biologic programs targeting Head and Neck Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

348

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CarcinomaActive, not recruiting

Transitional Cell CarcinomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Malignant GliomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Head and Neck CarcinomaPhase 2

Active, not recruiting

Transitional Cell CarcinomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Malignant GliomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

REOLYSIN

OOncolytics Biotech

Phase 2

1 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Vfend

PPrism Pharmaceuticals

Preclinical

—8

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Adenocarcinoma2 trials

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 2·NCT00998322·34 enrolled

Multiple Myeloma1 trial

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Unknown status·UUniversity of Leeds·Phase 1·NCT03015922·4 enrolled

Head and Neck Cancers1 trial

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Completed·OOncolytics Biotech·Phase 3·NCT01166542·167 enrolled

Malignant Glioma1 trial

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

Completed·OOncolytics Biotech·Phase 1·NCT00528684·18 enrolled

Breast Cancer1 trial

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT01656538·81 enrolled

8 more indications

Squamous Cell Carcinoma1 trial

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Completed·OOncolytics Biotech·Phase 2·NCT00998192·32 enrolled

Transitional Cell Carcinoma1 trial

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Withdrawn·OOncolytics Biotech·Phase 1·NCT02723838

Non-Small Cell Lung Cancer1 trial

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Completed·OOncolytics Biotech·Phase 2·NCT00861627·37 enrolled

Soft Tissue Sarcoma1 trial

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Completed·OOncolytics Biotech·Phase 2·NCT00503295·53 enrolled

Metastatic Colorectal Cancer1 trial

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Completed·OOncolytics Biotech·Phase 1·NCT01274624·36 enrolled

Metastatic Melanoma1 trial

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Completed·OOncolytics Biotech·Phase 2·NCT00984464·14 enrolled

Melanoma1 trial

REO13 Melanoma With of Without GM-CSF

Withdrawn·UUniversity of Leeds·Phase 1/2·NCT03282188

Head and Neck Carcinoma1 trial

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Completed·OOncolytics Biotech·Phase 2·NCT00753038·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for REOLYSIN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REOLYSIN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REOLYSIN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncolytics Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOncolytics Biotech

REOLYSIN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Adenocarcinoma2 trials

Multiple Myeloma1 trial

Head and Neck Cancers1 trial

Malignant Glioma1 trial

Breast Cancer1 trial

Squamous Cell Carcinoma1 trial

Transitional Cell Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Soft Tissue Sarcoma1 trial

Metastatic Colorectal Cancer1 trial

Metastatic Melanoma1 trial

Melanoma1 trial

Head and Neck Carcinoma1 trial

References

Drug Info

Quick Facts

Related News